Diligence memo · auto-generated · as of July 2, 2026

Electra Therapeutics, Inc.

Electra Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Electra Therapeutics, Inc. operates in Biotechnology, based in SOUTH SAN FRANCISCO.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Electra Therapeutics, Inc. has raised $134M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $134M on 2025-10-15.

Most recent recorded round closed around 2025-10-15.

Valuation (modeled)modeled

Provath models Electra Therapeutics, Inc. at approximately $962M (range $608M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.09× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era. Within the normal band (109% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 9 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 93% of Biotechnology peers (4293 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Kriya Therapeutics, Inc., Pathos AI, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp.

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.